47 stories found
Researchers have developed a highly effective urine-based diagnostic test capable of identifying more than 90 percent of bladder cancer cases. The breakthrough could significantly improve early detection rates and reduce the need for invasive procedures.
A significant advancement in the treatment of muscle-invasive bladder cancer (MIBC) has been published in the New England Journal of Medicine, highlighting the superior efficacy of enfortumab vedotin and pembrolizumab combination therapy over chemotherapy.
Pfizer has received FDA label expansion for its drug Padcev when used in combination with Merck’s Keytruda for the treatment of bladder cancer.
Particularly significant results, as stated, are shown in patients with bladder cancer, where early detection of the risk of recurrence can contribute to a better outcome from...
Doctors are praising the drug Durvalumab for its promising results in a clinical trial, where it successfully prevented bladder cancer tumors from returning and could spare patients from undergoing extensive surgery.
The Portuguese League Against Cancer has awarded new research grants for projects focusing on early detection of bladder cancer, prostate cancer biomarkers, and CAR-T cell monitoring.
In Croatia, three people are diagnosed with bladder cancer every day, about a thousand annually, and approximately 500 die. Unlike most cancers in Croatia, this one shows an upward trend...
Immunotherapy is making significant advancements in the treatment of bladder cancer, offering new hope for patients. This progress has led to increased calls for wider accessibility of these innovative treatments for all patients.
ImmunityBio has announced its acquisition of the U.S. rights to the Tokyo strain of Bacillus Calmette-Guérin (BCG), a vaccine primarily used against tuberculosis and also for bladder cancer treatment.
AstraZeneca announced that its Imfinzi combination therapy demonstrated improved survival rates in a study for bladder cancer patients.
Professor Piotr Wysocki, head of Oncology at Jagiellonian University, highlights that patients often ignore hematuria due to lack of pain, emphasizing it as an alarm signal for bladder cancer and the importance of early diagnosis.
An innovative combined therapy for advanced bladder cancer has shown promising results, with tumors disappearing in one-third of patients, yet it still awaits refund approval in Poland, sparking controversy.
Medical professionals are drawing attention to what they consider the primary indicator of bladder cancer, advising the public on symptoms to watch for.
In Croatia, three people are diagnosed with bladder cancer daily, a disease most commonly caused by smoking. It is often discovered late and has a low survival rate.
Bladder cancer is one of the most challenging tumors from diagnosis to treatment. The prognosis has improved in recent years, and intense scientific activity predicts great developments.
Deion Sanders and Karrueche Tran open up about their relationship during his bladder cancer battle and the emotional decision he offered her.
UroGen Pharma has submitted a New Drug Application (NDA) for UGN-103, an investigational treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
Konrad Nyland, an oil industry veteran, was diagnosed with bladder cancer but is ineligible for compensation as his specific cancer type is not on the government's approved list. This highlights a broader issue for many others in similar situations.
The European Union has approved a new combination therapy of pembrolizumab and enfortumab vedotin-ejfv for adult patients with surgically resectable bladder cancer, which has shown to reduce the risk of death by 50%.
Merck has received European Union approval for its Keytruda and Padcev combination therapy for the treatment of bladder cancer.
A personal account details the emotional and financial struggle to provide hospice care at home for a husband battling bladder cancer, highlighting the high cost of his final wish.
AstraZeneca has secured approval for its drug Imfinzi to treat an additional type of bladder cancer, expanding its therapeutic indications.
In Croatia, three individuals are diagnosed with bladder cancer every day, with rising mortality rates highlighting the urgent need for greater awareness and improved healthcare.
Even a single instance of blood in urine requires urgent urological consultation, as it can be the first and often only symptom of bladder cancer, which is too frequently detected late.
Genentech has received approval for a new bladder cancer indication for its drug, Tecentriq, expanding its therapeutic use.
This article discusses bladder cancer, highlighting its frequency, often silent nature, and the importance of early diagnosis as a critical prognostic determinant in oncology.
Merck & Co., Inc. (MRK) has been granted FDA Priority Review for its KEYTRUDA regimen in the treatment of muscle-invasive bladder cancer.
Pfizer and Astellas have received FDA priority review for their bladder cancer treatment, Padcev, when used in combination with Merck's Keytruda, signaling a potential expedited approval process for the therapy.
Johnson & Johnson (JNJ) has made significant progress in its bladder cancer treatment, reporting an impressive 89% response rate in recent trials. This development offers new hope for patients.
Bladder cancer is one of the most common and insidious cancers in men in Poland. Regular ultrasound examinations and oncological vigilance allow for early detection of the disease.
ImmunityBio's stock surged following the EU's approval of ANKTIVA for bladder cancer treatment.
A new Stanford Medicine study reveals that colorblind men face a 52% higher risk of bladder cancer death because they may not detect early warning signs.
For bladder cancer, the most crucial warning sign is the presence of blood in the urine. Recognizing this symptom is vital for early detection and treatment.
Pfizer (PFE) has announced that the FDA has approved PADCEV in combination with Keytruda for the treatment of MIBC (muscle-invasive bladder cancer).
Deion Sanders announced that he is now cancer-free, following his battle with bladder cancer which caused him to miss much of the last offseason.
Five hospitals in England and Wales have implemented a new, faster, and more accurate home-based test for diagnosing bladder cancer, replacing more invasive hospital procedures.
A study by Tata Memorial has found that radiation treatment can significantly cut the risk of bladder cancer recurrence by over 50%.
A study led by Portuguese scientists is paving the way for the application of a genetic test to diagnose metastatic bladder cancer, potentially accelerating treatment for patients.
Serbian patients with bladder cancer are seeing new advancements in treatment, with immunotherapy now becoming a focus, after years of waiting for modern therapeutic options that were already standard in many other countries.
Laparoscopic-robotic cystectomy is presented as the preferred surgical method for patients with invasive bladder cancer or severe benign conditions, promising reduced pain and quicker recovery.
May is recognized as Bladder Cancer Awareness Month, aiming to highlight a malignancy with a significant epidemiological footprint but disproportionately low public recognition.
Latvian scientists are working on a new, less invasive diagnostic method for bladder cancer, which is one of the most common oncological diseases. The new method aims to detect the cancer using urine analysis, making the process more patient-friendly.
Theralase has reported a complete response with its X-Ray-Activated Rutherrin(R) in a preclinical study for muscle-invasive bladder cancer. This finding suggests a promising new treatment approach for the disease.
ImmunityBio (IBRX) has announced that the NCCN Clinical Practice Guidelines have been updated to include ANKTIVA for the treatment of papillary-only non-muscle invasive bladder cancer (NMIBC).
The study, published in 'The Lancet Primary Care,' also indicates that in women, recurrent infections should prompt primary care physicians to order tests...
ImmunityBio's stock saw an increase after its bladder cancer therapy received approval in the European Union.